Multi-center experience with novel transplant conditioning regimens that incorporate 90Y ibritumomab tiuxetan (Zevalin®) Radioimmunotherapy (RIT) for autologous and allogeneic stem cell transplantation in patients with poor-risk B-cell non-hodgkin's lymphoma (NHL):: Targeted intensification and elimination of total body irradiation

被引：0
|
作者：
Molina, A
Nademanee, A
Winter, JN
Fung, HC
Inwards, DJ
Multani, P
Khouri, I
Raubitschek, A
White, CA
机构：
[1] IDEC Pharm, Med Affairs, San Diego, CA USA
[2] City Hope Canc Ctr, Dept Hematol & Bone Marrow Transplantat, Duarte, CA USA
[3] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA
[4] Mayo Clin & Mayo Fdn, Sch Med, Rochester, MN USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2003年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S48 / S48
页数：1
相关论文
共 40 条
  • [21] Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial
    Briones, Javier
    Novelli, Silvana
    Garcia Marco, Jose Antonio
    Francisco Tomas, Jose
    Bernal, Teresa
    Grande, Carlos
    Canales, Miguel
    Torres, Antonio
    Moraleda, Jose M.
    Panizo, Carlos
    Palmero, Fernanda
    Jarque, Isidro
    Hernandez, Miguel
    Gonzalez Barca, Eva
    Lopez, Dulce
    Caballero, Dolores
    BLOOD, 2012, 120 (21)
  • [22] Myeloablative conditioning autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning allogeneic SCT in children, adolescents, and young adults with poor-risk refractory/relapsed mature B-cell non-Hodgkin lymphoma
    El-Mallawany, Nader Kim
    Hochberg, Jessica
    Morris, Erin
    Harrison, Lauren
    Abrams, Debra
    Fabricatore, Sandra
    Horowitz, Tamar
    Beddows, Kimberly
    Panarella, Anne
    Londono, Magali
    Ehrenreich, Barbara
    Ayello, Janet
    Baxter-Lowe, Lee Ann
    Cairo, Mitchell S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 15 - 15
  • [23] A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL).
    Nademanee, A
    Molina, A
    Forman, SJ
    Kogut, N
    Yamauchi, D
    An, L
    White, CA
    Raubitschek, A
    BLOOD, 2002, 100 (11) : 182A - 182A
  • [24] Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
    Byung Woog Kang
    Won Seog Kim
    Chul Kim
    Geundoo Jang
    Sung Sook Lee
    Yoon Hee Choi
    Dae Ho Lee
    Sang We Kim
    Shin Kim
    Jin-Sook Ryu
    Jooryung Huh
    Jung Shin Lee
    Cheolwon Suh
    Investigational New Drugs, 2010, 28 : 516 - 522
  • [25] Updated results of high-dose yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHSCT) for poor-risk or refractory B-Cell non-hodgkin's lymphoma.
    Nademanee, Auayporn
    Raubitschek, Andrew
    Molina, Arturo
    Palmer, Joycelynne
    Tsai, Ni-Chun
    Krishnan, Amrita
    Kogut, Neil
    Forman, Stephen
    BLOOD, 2007, 110 (11) : 560A - 560A
  • [26] Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Kang, Byung Woog
    Kim, Won Seog
    Kim, Chul
    Jang, Geundoo
    Lee, Sung Sook
    Choi, Yoon Hee
    Lee, Dae Ho
    Kim, Sang We
    Kim, Shin
    Ryu, Jin-Sook
    Huh, Jooryung
    Lee, Jung Shin
    Suh, Cheolwon
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (04) : 516 - 522
  • [27] Radioimmunotherapy (RIT) with 90yttrium Zevalin Followed by BEAM Conditioning Regimen (Z-BEAM) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of High Risk Relapsed/Resistant Non Hodgkin's Lymphoma (NHL)
    Botto, Barbara
    Ciochetto, Chiara
    Bello, Marilena
    Passera, Roberto
    Benevolo, Giulia
    Boccomini, Carola
    Chiappella, Annalisa
    Freilone, Roberto
    Giunta, Francesca
    Nicolosi, Maura
    Orlandi, Erika
    Orsucci, Lorella
    Pecoraro, Clara
    Pregno, Patrizia
    Tonso, Anna
    Bisi, Gianni
    Vitolo, Umberto
    BLOOD, 2011, 118 (21) : 1343 - 1343
  • [28] 90y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)
    Nademanee, Auayporn P.
    Raubitschek, Andrew
    Palmer, Joycelynne
    Yamauchi, Dave
    Delioukina, Maria
    Popplewell, Leslie
    Sahebi, Firoozeh
    Smith, Eileen
    Stein, Anthony
    Kogut, Neil
    O'Donnell, Margaret
    Forman, Stephen J.
    BLOOD, 2009, 114 (22) : 1303 - 1303
  • [29] Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM
    Devizzi, Liliana
    Guidetti, Anna
    Seregni, Ettore
    Passera, Roberto
    Maccauro, Marco
    Magni, Michele
    Testi, Adele
    Di Nicola, Massimo
    Tarella, Corrado
    Matteucci, Paola
    Viviani, Simonetta
    Ruella, Marco
    Carlo-Stella, Carmelo
    Chiesa, Carlo
    Cox, Maria Cristina
    Bombardieri, Emilio
    Gianni, Alessandro M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2974 - 2976
  • [30] Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma (NHL):: Results with second-line therapy.
    Emmanouilides, C
    Murray, JL
    Vo, K
    Witzig, TE
    Darif, M
    Schilder, RJ
    Flinn, I
    Gordon, LI
    Wiseman, G
    Multani, P
    Molina, A
    BLOOD, 2003, 102 (11) : 306B - 307B
1234